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The pharmacokinetics and metabolism of ifosfamide
during bolus and infusional administration: a
randomized cross-over study
JM Singer, JM Hartley, C Brennan, PW Nicholson and RL Souhami
Department of Oncology, University College, 91 Riding House St, London Wl P 8BT, UK
Summary In a randomized cross-over trial, 11 patients received ifosfamide (IFOS) in 21-day cycles, which alternated between 3 g m-2 x
(2 or 3) days given as a 1-h bolus doses, or the same total dose as a continuous infusion. Patients who received four or more cycles also
alternated between two cycles on dexamethasone 4 mg 8 hourly for 3 days starting 8 h before IFOS, and two cycles off dexamethasone. A
total of 34 patient cycles were studied and serum and urinary levels of IFOS, 2 dechloroethylifosfamide (2DC), 3 dechloroethylifosfamide
(3DC), carboxyifosfamide (CX) and isophosphoramide mustard (IPM) were measured by thin-layer chromatography. No significant
differences could be detected in the areas under the curve (AUCs) of serum concentration, nor in the proportion of IFOS or its metabolites
found in the urine. There was no significant effect of dexamethasone on IFOS metabolism. These results indicate that there is no identifiable
pharmacokinetic basis for insistence on either bolus or infusional methods of IFOS administration.
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The oxazaphosphorine, ifosfamide (IFOS) is used to treat a large
number of malignancies (Brade et al, 1985). IFOS is a prodrug,
requiring biotransformation for activity or toxicity (Allen and
Creaven, 1972; Creaven et al, 1974). Metabolism appears to be
mainly in the liver where cytochrome P450 enzymes produce the
active intermediate 4 OH ifosfamide (Brock and Hohorst, 1963).
This metabolite exists in equilibrium with its tautomer aldo-
ifosfamide, which may be oxidized to carboxyifosfamide (CX) or
decompose spontaneously, by ,B elimination to produce iso-
phosphoramide mustard (IPM) (Brock, 1983). In addition to ring
oxidation, side-chain oxidation at the exo- or endo-cyclic nitrogen
may occur, yielding the metabolites 2- and 3-dechloroethyl
ifosfamide (2DC), (3DC) and chloroacetaldehyde (CAA) (Figure 1).
IPM is the ultimate alkylating metabolite of IFOS, causing
DNA interstrand cross-links. The metabolites responsible for
nephrotoxicity and neurotoxicity are unknown, although CAA has
been implicated as this is a reactive metabolite and produced in
large quantities (Wagner, 1994). Concentrations of 2DC and 3DC
are an indirect measurement of the unstable metabolite CAA, as
this is formed in equimolar amounts in the N-dechloroethylation
process.
A number of clinical pharmacokinetic studies have now been
published showing considerable inter- and intra-individual vari-
ability in serum and urine levels of parent drug and metabolites
(Creaven et al, 1974; Hartley et al, 1994; Boddy et al, 1993; 1995a;
1996). Some of this variability may be due to the differences in
detection method (Nelson et al, 1976; Wagner et al, 1994), the
schedule of administration, schedules, age (Lind et al, 1989a), the
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volume of distribution (Lind et al, 1989b), and the patient's age
and hepatic and renal function. Metabolic factors may also be
responsible such as genetic differences in the mixed function
oxidases or drug interactions involving the cytochrome P450
systems (Lind et al, 1990; Kaijser et al, 1993; 1994; Kurowski &
Wagner, 1993).
In standard IFOS doses (5-10 g m-2 per cycle), many schedules
ofadministration are used, such as a bolus dose in 30-60 min over
2-5 days and 24 or72 h continuous infusions. It is unclear whether
there is an optimal schedule, eitherfor anti-tumour effect orforthe
reduction of toxicity, and whether the pharmacokinetics of IFOS
and its principal metabolites are significantly influenced by
schedule. Animal studies have shown that four fractionated doses
of IFOS were superior to a single bolus in producing a higher
tumour cell kill for less haematological and urothelial toxicity
(Klein et al, 1984). Clinical studies are limited but also suggest
that continuous infusion IFOS is haematologically less toxic than
bolus doses forthe same anti-tumoureffect (Rodriguez et al, 1976;
Morgan et al, 1982; Klein et al, 1984; Anderson et al, 1993). Thus,
it is possible that increasing fractionation of IFOS may confer
some sparing of normal tissue toxicity. In children, Boddy et al
(1995b) have compared the pharmocokinetics of IFOS and
metabolites underbolus and infusion; however, there have been no
similar measurements in adults.
IFOS metabolism has been studied in vitro using rat and human
liver microsomes (Ruzicka & Ruenitz, 1992; Murray et al, 1994;
Walker et al, 1994). Weber and Waxman (1993) have shown that
pretreatment of rats with dexamethasone (DEX) increased liver
microsomal activation of ifosfamide sixfold. DEX is commonly
used in combination with ifosfamide because of its antiemetic
properties. It use may therefore alter the metabolic pattern of
ifosfamide with therapeutic or toxic consequences.
The aims of this study were, therefore, to compare the pharma-
cokinetics of 1-h bolus dose vs continuous infusion IFOS in a
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Figure 1 Metabolic pathways of ifosfamide
randomized cross-over study and to study the effect of DEX
administration on IFOS metabolism.
METHODS
Patient characteristics and sample collection
Patients with Ewings' sarcoma or soft tissue sarcoma were
randomly assigned to receive IFOS as either a 1 h bolus dose or a
continuous infusion for the first cycle and with or without DEX.
On subsequent cycles, the patients were crossed-over to the alter-
native modes for both IFOS and DEX. Seven patients received
IFOS at a dose of 3 g m-2 x 2 days each cycle and four received
IFOS 3 g m-2 x 3 days eachcycle. Bolus IFOS was administered as
a rapid 1 h infusion. The dose of sodium-2-mercaptoethane-
sulphonate (MESNA), the saline volume and rate were kept
constant in each arm ofthe study. All patients were studied for 2-6
cycles and thus crossed-over at least once (Figure 2). A total of34
patient/cycles were studied.
Eleven patients were studied, aged 23-71 years (four men and
seven women). Onepatientrequired a 15% dose reduction ofIFOS
after the first cycle because of bone marrow toxicity. All other
patients received 100% of the prescribed dose for each cycle
studied. Other co-administered drugs were: doxorubicin (11
patients), vincristine (one patient), paracetamol (four patients)
lorazepam (three patients) and metaclopramide (11 patients).
Blood samples were drawn immediately before treatment and at 2
to 3 h intervals throughout the 3-day period, except for 8 h night
intervals. Samples were centrifuged immediately at 3000 r.p.m. at
4°C, serum separated and stored at-20°C for subsequent analysis.
Urine samples were collected immediately before treatment and in
6 hourly time blocks for the 3-day period. Urine samples were
frozen immediately at-20°C for analysis.
Sample preparation and TLC
The parent drug, ifosfamide (IFOS), and its metabolites
(2-chloroethyl)-2-amino-tetrahydro-2-oxide-2H-1, 3, 2-oxazapho-
sphorine (2 dechloro- ethylifosfamide; 2DC), 2-(2-chloro-ethyl)-
amino-tetrahydro-2-oxide-2H- 1,3,2-oxazaphosphorine
(3-dechloroethylifosfamide; 3DC), 3-[N, N'-bis(2-chloroethyl-
amino) phosphinyloxy] propanic acid (carboxyifosfamide; CX)
and N, N'-bis (2-chloroethyl) phosphorodiamidic acid (iso-
phosphoramide mustard; IPM) were all prepared, authenticated
and kindly given by Asta Medica (Frankfurt, Germany).
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Figure 2 Treatment schedules for bolus (upper) and infusion (lower)
administrations
Extraction of parent drug and metabolites from patient urine
was as described previously (Boddy and Idle, 1992; Hartley et al,
1994). Samples were applied to prewashed XAD-2 columns and
eluted with methanol, dried and reconstituted in a small volume of
methanol. An aliquot (100 mg) ofsilicic acid and 3 ml ofmethanol
were added to the residue, vortexed and then centrifuged at
4000 r.p.m. for 10 min. The supematant was collected and evapo-
rated to dryness. Serum samples were treated similarly, but the
XAD-2 columns were washed with 0.05 M Tris buffer pH 5.5
before sample application.
Samples were then reconstituted in 70 ,l of methanol and 50 RI
was applied to high-performance thin-layer chromatography
(HPTLC) plates using a 'Linomat IV' TLC sample applicator
(Camag, Germany). The TLC plates were placed in glass tanks
containing dichloromethane-dimethylformamide-glacial acetic acid
(90:7:1) and allowed to run the full height of the plate twice to
ensure good resolution of all metabolites. After drying, the
plates were placed in a second mobile phase of chloroform-
methanol-glacial acetic acid (9:6:1) and allowed to run to a height
of3.0 cm twice. Once dry, the plates were then sprayed with 5% 4-
(4-nitrobenzyl)pyridine (NBP) in acetone/0.2 M acetate buffer pH
4.6 (8:2, v/v) twice, heated at 150°C for 10-15 min andthen dipped
in 3% potassium hydroxide in methanol to develop the plates.
Immediately afterdevelopment, the TLCplates were scannedusing
a reflecting laser densitometer. With the exception of serum IPM,
clean and reproducible chromatograms were obtained.
Concentrations were calculated using known standards of each
metabolite and urine and serum controls. Although IPM was
usually visible on the chromatograms, the recovery was poor. As a
consequence, the values of the serum IPM levels were regarded as
too unreliable and were disregarded. The recovery of serum IFOS,
3DC, 2DC and CX, all at 80jum, from the intemal controls was
95%, 80%, 60% and 40% respectively. The recoveries for IFOS,
3DC, 2DC, CX and IPM, all at 80 jim, in urine were 93%, 80%,
85%, 45% and 25% respectively. Thecoefficient ofvariation ofthe
urinary assays was previously reported to be 3.2%, 5%, 7%, 13%
and 32% respectively (Hartley et al, 1984) and for the serum
assays for IFOS, 3DC, 2DC and CX were 22%, 23%, 21% and
12% respectively.
Pharmacokinetic analyses of urinary and serum
concentrations
Urinary collections were made over consecutive 6-h periods. No
urinary drug or metabolite could be detected in the collections
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Figure 3 Serum concentration of IFOS and three metabolites in a patient
under bolus (A) and continuous infusion (B) administration. Eil, IFOS; *;
ZDC; O, 3DC; O, CX
after 60 h from the start of administration, and so, for each cycle,
the total urinary amounts of drug and metabolites over the first
60 h were calculated. These were then expressed as the molar
fractions of the administered dose, and are referred to hereafter
as a urinaryfraction ofdose.
For the serum determinations the area under the curve (AUC)
from time zero to infinity of the concentration vs time was
assessed primarily from the experimental data points by the linear
trapezoidal rule. In those cases in which the concentration of the
last sample had not reached the baseline, it was necessary to esti-
mate the area in the tailportion. This was based onextrapolation of
the lastfew datapoints using anexponential decay curve. To adjust
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Table 1 Mean and s.d. of peak serum concentrations (gM) of IFOS and its
metabolites aggregated over all patients and treatment cycles (total of n
cycles) and categorized according to mode of administration (A) or by
absence/presence of co-administration of dexamethazone (B). The Pvalues
are those relating to within patient comparisons from an ANOVA (see text)
A
Bolus dose Continuous infusion P-value
Mean s.d. n Mean s.d. n
IFOS 380.1 157.2 14 185.4 109.7 13 0.002
2DC 52.7 52.5 9 26.3 21.0 12 >0.05
3DC 104.9 39.9 10 92.5 97.3 12 >0.05
CX 69.1 34.2 10 56.4 55.6 10 >0.05
B
Dexamethasone No dexamethasone P-value
Mean s.d. n Mean s.d. n
IFOS 268.9 136.4 15 308.2 202.4 12 >0.05
2DC 44.2 50.8 11 30.3 19.8 10 >0.05
3DC 111.0 97.9 12 82.7 32.6 10 >0.05
CX 71.3 63.9 9 55.8 23.2 11 >0.05
Table 2 Mean and s.d. of AUC (mM h) of IFOS and its metabolites
aggregated over all patients and treatment cycles (total of n cycles) and
categorized according to mode of administration (A) or by absence/presence
of co-administration of dexamethazone (B)
A
Bolus dose Continuous infusion
Mean s.d. n Mean s.d. n
IFOS 6.89 2.03 14 6.96 4.40 13
2DC 0.98 1.27 9 0.64 0.44 12
3DC 3.14 2.01 10 2.92 2.73 12
CX 0.91 0.55 10 1.52 2.36 10
B
Dexamethasone No dexamethasone
Mean s.d. n Mean s.d. n
IFOS 7.20 4.10 15 6.57 2.09 12
2DC 1.04 1.12 11 0.50 0.41 10
3DC 3.33 3.00 12 2.65 1.38 10
CX 1.57 2.51 9 0.92 0.48 11
for minordifferences in dose, all values ofAUC and Cmax, the peak
concentration, were normalized to correspond to a total dose of
11.54 g, the mean value over all patients and cycles.
Statistical methods
Analyses of variance (ANOVA) were made using the SPSS statis-
tical package (SPSS, Chicago, IL, USA). As observations were
generally not available for all combinations of the factors of
interest (for example patient number, bolus/infusion administra-
tion, cycle number, use/absence of dexamethasone), it was only
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Figure 4 Scattergram with overall mean and s.e. of the area under the
curve (AUC) of the serum concentration of ifosfamide and metabolites for all
cycles of bolus and infusion administrations
possible to test forthe main effects. In all analyses the first ofthese
factors, patient number, was always included in the ANOVA
model. With the cross-over design of the investigation, this
allowed for the testing for any effects due to any of the remaining
three factors on a within-patient basis. Effects were regarded as
statistically significant for P < 0.05.
RESULTS
Eleven patients were studied over a total of 34 cycles oftreatment.
Of these, two patients declined venesection and one had insuffi-
cient urine collection. Seven patients were treated with IFOS over
48 h and four patients were treated with IFOS over 72 h.
Serum levels
Figure 3 shows typical measurements of serum concentration of
IFOS and metabolites, measured in the infusion and the bolus
treatments of a patient receiving IFOS over 48 h. The concentra-
tion profile of IFOS shows an immediate rise after the bolus
administration and a gradual rise after infusional administration.
There are minordifferences in the profiles ofthe metabolites in the
example in Figure 3, but these were not seen systematically in the
rest ofthe dataset. In general, comparing the two types ofadminis-
tration, the serum metabolite profiles were quite similar in both
shape and magnitude.
Summary values
Summary values of Cmax for all patients and cycles under the two
administration modes, and with and without DEX are listed in
Table 1. The ANOVA showed no effect due to DEX but the effect
of the administration mode was significant for IFOS (F = 13.3;
d.f. 1,13; P = 0.002) but not for any of the three metabolites. In
summary, therefore, for the peak serum concentrations of IFOS
and its metabolites, only those ofIFOS were significantly different
(by a factor of2.05) in the bolus dose against the infusion.
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Table 3 Mean and s.d. of urinary fraction (%) of IFOS and its metabolites
aggregated over all patients and treatment cycles (total of n cycles) and
categorized according to mode of administration (A) or by absence/presence
of co-administration of dexamethazone (B). The P-values are those relating
to within patient comparisons from an ANOVA (see text)
A
Bolus dose Continuous infusion P-value
Mean s.d. n Mean s.d. n
IFOS 21.0 9.0 16 25.2 14.5 15 >0.05
2DC 5.3 2.1 16 5.6 3.5 15 >0.05
3DC 12.4 4.9 16 12.2 6.1 15 >0.05
CX 16.1 6.8 16 13.5 8.7 15 >0.05
IPM 10.2 6.9 16 9.5 3.7 15 >0.05
B
Dexamethasone No dexamethasone P-value
Mean s.d. n Mean s.d. n
IFOS 20.9 6.4 18 26.0 16.9 13 >0.05
2DC 5.1 2.5 18 5.9 3.2 13 >0.05
3DC 11.8 5.8 18 13.0 5.0 13 >0.05
CX 15.8 6.3 18 13.5 9.6 13 >0.05
IPM 10.5 3.8 18 9.1 7.4 13 >0.05
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Table 4 Urinary fraction of dose as a percentage: grand mean and within-
patient standard deviations
Grand mean Within-patient s.d.
IFOS 23.0 11.1
2DC 5.4 2.3
3DC 12.3 4.6
CX 14.8 7.2
IPM 9.9 4.8
Total 66.4 20.6
Apreliminary analysis was made on the AUC ofthose treatment
cycles consisting of a pair ofbolus doses at a 24 h interval. Owing
to the rapid decay ofthe concentration ofIFOS after the first dose,
it was possible to resolve the AUC into components contributed by
each of the two doses. In ten treatment cycles in six patients, the
AUC components contributed by the first and second dose had
means of 4.96 mm h and 2.56 mm h respectively. A paired t-test
showed that these were significantly different (t = 3.33, d.f. = 9, P
= 0.009) and this seems to give clear evidence of induction of
IFOS metabolism. It was notpossible to apply this type ofanalysis
to the AUCs ofthe metabolites as it was impossible to resolve the
AUC into the components contributed by the two doses.
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Figure 5 Scattergram with overall mean and s.e. of the urinary fraction of dose (as percentage) for ifosfamide and metabolites for all cycles of bolus and
infusion administrations
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Subsequent analyses were made in terms of the total AUC over
the treatment cycle. Figure 4 gives a scatter plot of AUCs taken
over all patients and cycles for bolus and infusion administrations,
and Table 2 gives corresponding summary data. ANOVA of these
with DEX, administration mode and cycle number as factors,
either singly or in combination did not reveal any significant
effects.
Urine analysis
For each cycle the total urinary amounts of IFOS and metabolites
were expressed as molar fractions of the amount of IFOS given.
Patients receiving 72 h treatments were also included in this part
of the analysis, giving a total of 31 cycles in ten patients. Figure 5
gives a scatter plot ofthese values, for bolus and infusion adminis-
tration, and Table 3 gives corresponding summary data. The
ANOVA did not reveal any significant differences on the urinary
fractions of parent drug or metabolite of bolus/infusion adminis-
tration or of absence/presence of DEX co-administration. The
effect of sequential cycles was also examined, but the analysis did
not reveal significant alteration in the proportion of metabolite
generated with successive cycles. Thus, it appeared unlikely that
there was induction of IFOS metabolism between successive
cycles.
As the patients underwent more than one cycle of treatment, it
was possible to derive from the ANOVA an estimate ofthe within-
patient variability (i.e. from cycle to cycle) ofthe urinary fractions.
For this, all urinary results were pooled (as no significant differ-
ences due to administration of DEX had been detected) and the
values of the within-patient s.d. given in Table 4. These results
reveal aconsiderable degree ofwithin-patient variability in urinary
excretion from cycle to cycle.
DISCUSSION
Ifosfamide is commonly administered, either as a series of intra-
venous boluses over several days or as an infusion, yet there has
been no direct pharmacokinetic comparison between the two
schedules. Klein et al (1984) reported a study in which rats were
treated with either a single or four bolus doses and demonstrated
that the fractionated IFOS regimen resulted in a decreased LD50/30
and higher tumour cell kill. Phase I/Il clinical studies also indi-
cated that fractionating the dose resulted in less microscopic and
macroscopic haematuria (Rodriguez et al, 1976; Klein et al, 1984).
More recently, Anderson et al (1993) randomized 159 patients
with small-cell lung cancer to receive 5 g m -2 IFOS, either over
24 h or 7 days with an ambulatory pump infusion, and found
the survival to be the same but the haematological toxicity to be
less in the 7-day infusion arm.
Previous pharmacokinetic studies have been reviewed recently
by Wagner (1994) and Kaijser et al (1994). A number of studies
were performed on patients who received either infusional or bolus
IFOS, but which measured only the parent drug (Creaven et al,
1974; Allen and Creaven, 1975; Nelson et al, 1976). Of the reports
that have made measurements on both IFOS and its principal
metabolites, Kurowski and Wagner (1993) studied 11 patients
receiving five daily boluses of IFOS and measured IFOS, 2DC,
3DC, and CAA and the unstable 4 hydroxyifosfamide. Other
groups (Boddy and Idle, 1992; Boddy et al, 1993; 1995a; Hartley
et al, 1994) have measured both IFOS and its principal metabolites
in patients receiving infusional IFOS. In general, these studies have
shown that there is induction of IFOS metabolism after approxi-
mately 3 days oftreatment. With repeated daily bolus doses over 5
days, Lind et al (1989) reported a decrease in half-life that forms a
mean of 6.2 h on the first day to 3.8 h on the fifth day and that this
decrease was almost entirely explained by an increase in clearance.
In the example shown (Figure 3) ofthe profiles ofeach metabo-
lite, there are some minor differences between that 1 h bolus and
infusion administrations. However, over the whole dataset little
systematic difference could be discerned, and cross-over compar-
ison between 1 h bolus and infusional IFOS did not reveal a
significant difference in the AUC. This is compatible with the
cross-over study in 17 children reported by Boddy et al (1995b).
Any alteration in the relative amounts of metabolites produced
may be of therapeutic advantage. Less dechloroethylation would
result in a reduction of 2DC, 3DC and CAA and, possibly, less
toxicity. From our data, it appears that with bolus administration
the metabolites are sufficiently slow to appear in the serum their
concentration profiles are essentially no different from that with
infusion administration. Thus, any differences in therapeutic or
toxic effect of the two administration regimes do not appear to be
reflected in differences in serum pharmacokinetics of these
metabolites.
In those patients receiving cycles of two bolus doses, the AUC
attributable to the second dose was less than that of the first.
Although this was not the primary purpose of this investigation
and the result was based on small numbers, it offers some evidence
of induction and it parallels the findings of Lind et al (1989)
referred to above.
In the second part ofthe study, we examined the effect ofDEX on
the metabolism ofIFOS. Weberand Waxman (1993) showed that, in
rats, phenobarbital induced cytochrome P450 subfamily 2B1 for the
metabolism of both IFOS and cyclophosphamide. They also
reported that DEX induced cytochrome P450 3A to increase the
metabolism of IFOS sixfold (but not that ofcyclophosphamide) and
suggested the co-administration of DEX clinically may enhance
response. Walker et al (1994) have suggested that the same enzyme
is responsible for both IFOS activation and dechloroethylation in
humans. In our study, patients were crossed over from no DEX to
DEX 4 mg t.d.s. for 3 days, the latter being chosen as that in routine
clinical use in conjunction with antiemetics. No difference in any of
the pharmacokinetic parameters could be detected and so, at these
dose levels of DEX, changes in the measured IFOS metabolites do
not appear important. This is of clinical interest as DEX is widely
used as an antiemetic for cytotoxic chemotherapy. For cyclo-
phosphamide Yule et al (1995) reported an association of DEX
pretreatment in children with the presence of serum ketocyclophos-
phamide. In our patients the levels of ketoifosfamide were barely
detectable by the TLC technique and we were unable to confirm or
deny any such similar association.
Several previous reports have drawn attention to the wide vari-
ability in IFOS handling between patients, and this is the case in
our patients. However, it is apparent from our results (Table 4) that
there is also a large degree of within-patient variability, i.e. from
cycle to cycle. The total fraction of dose recovered in urine, for
example, has a within-patient s.d. that corresponds to a coefficient
of variation of 31%. Only a small part of this variability can be
attributed to uncertainties in the experimental technique. The coef-
ficient of variation of this assay has been reported previously by
this group and for IFOS was found to be 4% (Hartley et al, 1994).
Boddy et al (1996) recently reported a high degree of within-
patient variability in ifosfamide pharmacokinetics in children. In
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11 patients the within-patient variation from cycle to cycle in
serum AUC ofdrug was twofold and that ofmetabolites was up to
tenfold. The large variability from cycle to cycle may mean that
differences due to saturation or induction, stemming from mode of
administration, or of the co-administration of DEX, may not be
revealed, even in cross-over studies such as that reported here.
Indeed, it could be argued that any such differences would be
relatively unimportant clinically compared with the inherent
variability of drug handling within a patient.
We conclude that, against this pattern of variability in drug
handling in patients from cycle to cycle, we can detect no consis-
tent significant differences in the serum pharmacokinetics, nor the
urinary excretion, of IFOS and its metabolites, when under bolus
as against infusion administration. From the pattern of serum
pharmacokinetics and urinary excretion in adults, we can find no
reason to prefer one regimen over the other in the clinical use of
the drug. This is broadly in line with the conclusions ofBoddy et al
(1995b) for children.
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